ValiRx PLC Director/PDMR Shareholding (5388Z)
15 March 2017 - 8:33PM
UK Regulatory
TIDMVAL
RNS Number : 5388Z
ValiRx PLC
15 March 2017
ValiRx Plc
("ValiRx" or "the Company")
PDMR / Director Dealing
London, UK., 15 March 2017: ValiRx Plc (AIM: VAL), a clinical
stage biotechnology company, announces that it has received the
following notifications from PDMRs of dealings in the Company's
shares, all of which related to the issue of shares announced on 2
March 2017 for which Admission to trading on AIM occurred on 15
March 2017.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name Satu Vainikka
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name George Morris
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Chief Operating Officer
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ----------------------------------------------------------------------------------
a) Name Gerry Desler
---- -------------------------------------- ------------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------------------------
a) Position/status Finance Director
---- -------------------------------------- ------------------------------------------
b) Initial notification/ Initial Notification
Amendment
---- -------------------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- ----------------------------------------------------------------------------------
a) Name ValiRx Plc
---- -------------------------------------- ------------------------------------------
b) LEI N/A
---- -------------------------------------- ------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
---- ----------------------------------------------------------------------------------
a) Description of the
financial instrument,
type of instrument
----
Identification code GB00BWWYSP41
b) Nature of the transactions Issue of Ordinary Shares
---- -------------------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- -------------------------------------- --------------------------- ----------
2.50 p 400,000
--------------------------- ----------
d) Aggregated information
----
- Aggregated volume 400,000
- Price 2.50 p
-------------------------------------- -----------------------------------------------
e) Date of the transaction 15 March 2017
---- -------------------------------------- ------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
---- -------------------------------------- ------------------------------------------
***S ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Tel: +44 (0) 7736
Manager 564 686
mark.treharne@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray / Jo Turner
Beaufort Securities Limited Tel: +44 (0) 207
(Joint Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGCGDXIDBBGRU
(END) Dow Jones Newswires
March 15, 2017 05:33 ET (09:33 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024
